Managing Perioperative Anticoagulation. Edie Shen MD

Similar documents
Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest

Perioperative Management of the Anticoagulated Patient

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Perioperative Anticoagulation Management

Atrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Disclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine

Do s and Don t of DOACs DISCLOSURE

Bridging anticoagulation definition

Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules

Intrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway

Perioperative Management of Anticoagulation

Prostate Biopsy Alerts

Obesity, renal failure, HIT: which anticoagulant to use?

Challenges in Anticoagulation and Thromboembolism

Clinical Practice Committee Anticoagulation Bridging Document

Oral Anticoagulation Drug Class Prior Authorization Protocol

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging

A Cascade of Updates: Hot Topics in Anticoagulation

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

ANTICOAG & THROMBOSIS CASES

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Rapid Fire-Top Articles You Need to Know

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Perioperative VTE Prophylaxis

Direct Oral Anticoagulants

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

ALL BLEEDING STOPS EVENTUALLY! PATRICK C. CULLINAN, DO FCCM, FACOI, FACOEP SAN ANTONIO, TX

What s new with DOACs? Defining place in therapy for edoxaban &

Direct Oral Anticoagulants An Update

ANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY

Update in Perioperative Anticoagulation and Antiplatelet management

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Disclosure and Conflict of Interest

Anticoagulants: Agents, Pharmacology and Reversal

They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)

Novel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015

Joost van Veen Consultant Haematologist

Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD

DOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.

NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT

Drug Class Monograph

DEEP VEIN THROMBOSIS (DVT): TREATMENT

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations

Disclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Anticoagulation: Novel Agents

Clinical issues which drug for which patient

Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi

The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI,

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia

The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives

Disclosures. Objectives. Management of Anticoagulation in The Patient with Atrial Fibrillation 4/3/2018

Perioperative Management of Warfarin Interruption

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

Clinical Guideline for Anticoagulation in VTE

Blood Day for Primary Care

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

New Antithrombotic Agents DISCLOSURE

Asif Serajian DO FACC FSCAI

Stepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg

To Bridge or Not to Bridge? Preop Evaluation of the Patient on Coumadin

Updates in Management of Venous Thromboembolic Disease

Endoscopy in the Era of Anti- Platelet and Anti-Coagulation

EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY

Updates in Diagnosis & Management of VTE

Cases & Panel Discussion

Updates in Atrial Fibrillation

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Treatment Options and How They Work

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

New Anticoagulants Therapies

Updates in Pharmacotherapy for Peri-Operative Anticoagulation Management

ADVANCES IN ANTICOAGULATION

Spontaneous Atrial Fibrillation and Noacs and Reversal agents

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention

NOACS/DOACS*: COAGULATION TESTS

Professional Practice Minutes December 7, 2016

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Mabel Labrada, MD Miami VA Medical Center

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Venous Thromboembolism Prophylaxis: Checked!

Top 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE

New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY

Transcription:

Managing Perioperative Anticoagulation Edie Shen MD

Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis) Edoxaban (Savaysa)

Case #1 63 yo man with history of COPD, claudication and mechanical AVR, anticoagulated with warfarin slated for an aorto-bifemoral bypass

Warfarin: Bridging Douketis et al. Hematol Oncol Clin N Am 30 (2016) 1073 1084

Warfarin: Bridging

Warfarin: Bridging

Warfarin: Bridging

Warfarin: Bridging

Case #1 63 yo man with history of COPD, claudication and mechanical AVR, anticoagulated with warfarin slated for an aorto-bifemoral bypass No need for bridging

Case #2 78 yo patient with Afib, DM, RA, HTN, CHF EF 35%, anti-coagulated with warfarin Scheduled for ZFEN

Warfarin: Bridging x

Warfarin: Bridging

Warfarin: Bridging

Warfarin: Bridging

Warfarin: Bridging

Atrial Fibrillation - BRIDGE trial 1884 patients with Afib with peri-procedural warfarin interruption Exclusion Criteria Mechanical valve Recent TE event 10% Recent CVA/TIA 0% Dalteparin Thromboembolism * None Bleeding Douketis et al, Engl J Med 2015;Jun 22

Atrial Fibrillation: In General, don t Bridge May consider if very high CHADS2, or past CVA BRIDGE trial mean CHADS2 score 2.3

Case #2 78 yo patient with Afib, DM, RA, HTN, CHF EF 35%, anti-coagulated with warfarin Scheduled for ZFEN no bridging

Case #3 60 yo woman with HTN, poorly controlled DM PE 6 weeks ago following spine surgery on warfarin Presents with ischemic RLE Diagnosed with critical limb ischemia

Warfarin: Bridging x

Warfarin: Bridging

Warfarin: Bridging

Warfarin: Bridging

Warfarin: Bridging

Case #3 60 yo woman with HTN, poorly controlled DM PE 6 weeks ago following spine surgery on warfarin Presents with ischemic RLE Diagnosed with critical limb ischemia LMWH bridging to heparin gtt

Perioperative Warfarin Management Typically discontinue warfarin five days before elective surgery Last dose of warfarin is given on day minus 6 Many suggest day before surgery INR with 1 or 2 mg vit K for INR>1.5 Preoperative timing of bridging Start LMWH bridging three days before a planned procedure Last dose enoxaparin 24 hours prior to surgery. If a once-daily regimen is given (eg, dalteparin 200 international units/kg), one half of the total daily dose is given 24 hours prior to surgery.

Restarting the Warfarin Surgeon Discretion POD0 or 1 warfarin More likely to bridge post-operatively Full-dose bridging generally at 48-72 hours Can start proph dose Enoxaparin 40 qd Exoxaparin 40 BID

Case #4 58 yo man with history of Afib, TIA 2013, CKD stage 3b (Cr 2.0) on dabigatran scheduled for fem-pop bypass

Overview of DOACs Preferred anticoagulant Half the risk of ICH Faster onset Renal clearance Contraindicated liver disease Not reversible

Sites of Action Nutrients 2015, 7(11), 9538-9557;

Sites of Action Nutrients 2015, 7(11), 9538-9557;

Sites of Action Dabigatran Nutrients 2015, 7(11), 9538-9557;

Sites of Action Rivaroxaban Apixaban Edoxaban Dabigatran Nutrients 2015, 7(11), 9538-9557;

Preoperative Management: DOACs Generally no bridging is needed Postoperative ileus Only one has a reversal agent: Idarucizumab (Praxbind)

Case #4 58 yo man with history of Afib, TIA 2013, CKD stage 3b (Cr 2.0) on dabigatran scheduled for fem-pop bypass Hold dabigatran for 96 hours

Preoperative Management: DOACs

Postop: Restarting DOACs Generally restart full dose DOACs 24 hours after minor surgery 48-72 hours after major surgery Can start prophylactic dose of anticoagulants at first Dalteparin 5000 IU daily Enoxaparin 30 mg BID Dabigatran 75-110 BID Rivaroxaban 10-15 mg qd Apixaban 2.5 mg BID.

Holding DOACs Preop: High Risk surgery Rivaroxaban Dabigatran Apixaban Edoxaban 48 hours 48-120 hours 48-72 hours 48 hours

2016 Updates to CHEST Guidelines re: VTE Proximal DVT/PE: Rivaroxaban/Apixaban Unprovoked 1st proximal DVT/PE: Extended Isolated distal DVT: treat or not? Subsegmental PE look for proximal DVT